Capsaicin 8% Patch for SCI Pain: A Small, Specific Signal

A peripheral target may matter in a central injury

Capsaicin 8% patch has a plausible job in one narrow form of spinal cord injury (SCI) pain: focal pain at the injury level, where peripheral sensory fibers may still provide an accessible target. The biology is specific. After SCI, changes in sensory signaling can increase TRPV1 activity in dorsal root ganglion neurons and skin-innervating C-fibers near the injury level. Capsaicin activates TRPV1 intensely, then temporarily defunctionalizes those pain-sensing fibers. That could reduce signals arriving from the treated patch of skin.

It is an appealing hypothesis, but human evidence remains very thin. The only published randomized trial in SCI enrolled 11 people. Its active-treatment arm had a 35% reduction in visual analog scale (VAS) pain at two weeks and a 29% reduction at four weeks. Those figures deserve attention, not certainty. The trial was too small to provide a reliable population effect estimate, and it did not separate at-level pain from below-level pain—the distinction most likely to determine whether a topical peripheral treatment can help.

For people without SCI who are considering capsaicin for a vague "neuropathy" complaint, this is not a green light. A drug that works by acting on surviving peripheral TRPV1-bearing fibers will not automatically help pain driven mainly by central sensitization or by loss of those fibers.

What the 8% patch actually does

Capsaicin is the pungent compound in chili peppers, but an 8% capsaicin patch is a medical treatment, not a spicy home remedy with better branding. TRPV1 is found on small-diameter C-fiber and Aδ nociceptors. Sustained, high-concentration stimulation initially produces burning and then reduces signaling from capsaicin-sensitive nerve terminals. A 2023 review of capsaicin and TRPV1 describes this defunctionalization as involving depletion of substance P and other neuropeptides from C-fiber terminals.

The mechanism explains both the interest and the limits. In SCI, loss of normal descending inhibition and altered peripheral signaling may increase TRPV1 expression in relevant peripheral neurons. A patch applied over a painful, localized at-level area could therefore reach a biologically relevant target. Below-level SCI pain may instead be maintained predominantly by central sensitization. A patch on the skin cannot assume control of a pain process maintained elsewhere in the nervous system.

The SCI trial found a signal, not a settled treatment effect

In the 2023 randomized crossover trial by Olusanya et al., 11 participants with SCI-associated focal neuropathic pain received an 8% capsaicin patch and a 0.025% capsaicin active placebo. In the active arm, VAS pain fell 35% from baseline at week 2 and 29% at week 4. Participants also improved on the Spinal Cord Independence Measure (SCIM), a functional measure that includes mobility.

Those are encouraging directions of travel. They do not establish that the patch reliably produces a 35% pain reduction in SCI. The study had only 11 participants, and the reported evidence does not provide a confidence interval around that point estimate. Without enough participants, chance differences and individual response patterns can dominate the result.

The comparator adds another complication. The 0.025% patch was an active placebo, not an inert patch. Low-dose capsaicin can activate TRPV1, which may reduce the measured difference between study periods. That could make the 8% patch look less distinct than it would against no active treatment. But it does not solve the trial's central precision problem: the study cannot tell us the true size of the benefit.

The crossover design also has a built-in concern for this drug class. Capsaicin-induced defunctionalization can persist for weeks. If nerve fibers had not fully recovered before participants crossed into the control period, carryover could compress pain scores during that period. A larger parallel-group trial would avoid that ambiguity.

Function improved; quality of life did not

The trial's outcomes did not all move together. SCIM scores improved in the active arm, while World Health Organization Quality of Life (WHO-QOL) scores did not improve. Pain and mobility can change without moving a broad quality-of-life score, especially after SCI, when function, sleep, mood, caregiving needs, and complications can all shape daily life. The 12-week observation window and sample of 11 also leave little room to detect a quality-of-life difference.

Still, the null WHO-QOL result matters. A lower pain score is a patient-relevant outcome, but it does not guarantee a large enough change to improve overall quality of life. The trial cannot distinguish a clinically modest effect from a potentially useful effect that the study was too small and short to capture on WHO-QOL.

Established uses provide a useful benchmark—not a shortcut

High-concentration capsaicin has better evidence in post-herpetic neuralgia (PHN) and HIV-associated distal sensory polyneuropathy. A 2017 Cochrane review pooled about 2,442 adults across six randomized trials. For PHN, the relative risk of achieving at least 30% pain reduction versus active control was 1.28 (95% confidence interval, 1.09 to 1.52), with a number needed to treat of 8.8 (95% CI, 5.3 to 26). That is modest efficacy, not a dramatic response for most patients.

The contrast helps interpret the SCI result. The Cochrane estimate comes from far more participants and gives a confidence interval; the SCI trial does neither. It also does not prove that a patch effective in PHN or HIV-related neuropathy will work across SCI pain types. Clinical response depends on whether the treated skin contains intact, sensitized TRPV1-bearing fibers.

Painful diabetic peripheral neuropathy offers a cautionary comparison. A 2023 review of painful diabetic peripheral neuropathy treatments describes topical capsaicin as having a limited and inconsistent role. The proposed explanation fits the biology: progressive intraepidermal C-fiber degeneration can reduce the fiber population that capsaicin targets. That is not proof that below-level SCI pain will fail to respond, but it supports the need to identify the pain phenotype before treating it as a peripheral target.

The safety issue is unusually serious in SCI

Application-site burning, pain, and redness are common with high-concentration capsaicin. In a person with intact sensation, worsening burning can serve as a warning that prompts assessment or patch removal. SCI can remove that warning system at and below the injury level.

A 2023 case report documented a second-degree burn with mobility sequelae after high-concentration topical capsaicin. The report was not in an SCI population, so it cannot quantify burn risk after SCI. It does establish that serious tissue injury can occur. For someone with reduced protective sensation, inability to feel excessive burning makes that risk more concerning, not less.

That means this is not a sensible self-experiment. SCI use would require clinician-directed application, inspection of the skin, and an approach tailored to the patient's sensory status. No SCI-specific repeat-application data tell us how often treatment should be repeated or whether recovery of treated fibers differs from other approved-use populations.

What a decisive trial would look like

The next study should be a properly powered parallel-group randomized trial that prospectively separates at-level from below-level neuropathic pain. It should measure pain, function, and quality of life over a longer follow-up period, report confidence intervals, and use safety procedures designed for impaired sensation. It should also establish what happens with repeat applications.

Capsaicin 8% patch has a credible mechanistic rationale for focal at-level SCI pain and one underpowered proof-of-concept trial. It does not yet have evidence strong enough for uncritical adoption across SCI pain, and it has no rationale as a general biohacker remedy for neuropathy.

The practical conclusion is narrow. Discuss this treatment with an SCI pain specialist only after the pain phenotype and the skin's protective sensation have been assessed. The 35% VAS reduction is an interesting lead. It is not a dose of certainty.